Parkinson's UK invests in drug development Date 23 August 2021 We've invested a further £490,000 to support the development of drugs to protect mitochondria and treat Parkinson's.
Oxford researchers find molecule that may slow or stop the progress of Parkinson's Date 29 September 2020 Parkinson's UK funded research suggests it may be possible to prevent the formation of protein clumps that cause problems in Parkinson's by using microscopic tweezers that pull apart the proteins. This could pave the way for a therapy that could slow or stop the progression of the condition.
Results from stem cell therapy surgery announced Date 14 May 2020 A US-based team has published results after treating one individual with an experimental stem cell therapy. The therapy involved surgically transplanting new brain cells, made from the patient's own skin, into the brain of a man with Parkinson's.
Promising results from a phase II study for people with early-stage Parkinson’s Date 8 October 2019 A phase II clinical trial of tavapadon, a drug developed by Cerevel Therapeutics, has shown improvements in movement symptoms. The results have been announced on the company website.
Investing in a new treatment for dyskinesia Date 24 January 2018 We're partnering with US company Neurolixis to accelerate the development of a drug that could prevent dyskinesia, a debilitating side effect of Parkinson's medication.
Research on caffeine to diagnose Parkinson's Date 4 January 2018 Researchers in Japan have discovered that people with Parkinson's may have lower levels of caffeine in their blood after drinking tea and coffee.
Tapeworm drug shows promise for Parkinson's Date 12 December 2017 Research supported by Parkinson's UK has identified a medicine used to treat tapeworm infections which could lead to new treatments for people with Parkinson's.
Research on the consequence of weight loss in Parkinson's Date 17 November 2017 New research shows weight loss is linked to poorer outcomes for those with Parkinson's.
Further evidence on the benefits of pimavanserin Date 25 September 2017 UK researchers publish further evidence highlighting the need to licence pimavanserin for hallucinations and delusions in Parkinson's.
Asthma drugs could decrease risk of Parkinson's Date 4 September 2017 New research suggests that a type of asthma drug that activates a protein called beta-adrenoceptors, may decrease risk of Parkinson's.
